



Title: Depressive symptoms are associated with objectively measured sleep 
parameters in kidney transplant recipients 
Subtitle: Depression, sleep and kidney transplantation 
Katalin Z Ronai MD1, Andras Szentkiralyi MD, PhD1,2, Alpar S Lazar PhD1,3, Akos Ujszaszi MD, PhD4, Csilla 
Turanyi MD, PhD1, Istvan Mucsi MD, PhD1,5 Robert Bodizs PhD1,6, Miklos Z Molnar MD, PhD7,8, Marta 
Novak MD, PhD1,9 
1 Inst. of Behavioural Sciences, Semmelweis University, Budapest, Hungary, 
2 Inst. of Epidemiology and Social Medicine, University of Muenster, Muenster, Germany 
3 John van Geest Centre for Brain Repair, Department of Clinical Neurosciences University of Cambridge, 
Cambridge, United Kingdom 
4 Inst. of Pathophysiology, Semmelweis University, Budapest, Hungary 
5 Dept. of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Canada  
6 Dept. of General Psychology, Pázmány Péter Catholic University, Budapest, Hungary 
7 Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, TN, USA 
8 Dept. Transplantation and Surgery, Semmelweis University, Budapest, Hungary 





address: Toronto General Hospital  
200 Elizabeth St, Toronto, ON M5G 2C4, Canada 







Keywords: depression, stage 2 sleep, REM sleep, slow wave sleep, kidney transplant recipients 
Introduction: Both depression and sleep complaints are very prevalent among kidney transplant (kTx) 
recipients. However, details of the complex relationship between sleep and depression in this 
population are not well documented. Thus we investigated the association between depressive 
symptoms and sleep macrostructure parameters among prevalent kTx recipients. 
Methods: 95 kTx recipients participated in the study (54 males, mean age 51±13 years, BMI 26±4 
kg/m2, estimated glomerular filtration rate 53±19 ml/min/1.73m2). Symptoms of depression were 
assessed by the Center for Epidemiologic Studies - Depression Scale (CES-D). After one-night 
polysomnography each recording was visually scored and sleep macrostructure was analysed. 
Results: The CES-D score was significantly associated with the amount of stage 2 sleep (r=0.20, p<0.05), 
REM latency (r=0.21, p<0.05) and REM percentage (r=-0.24, p<0.05), but not with the amount of slow 
wave sleep (r=-0.12, p>0.05). In multivariable linear regression models the CES-D score was 
independently associated with the amount of stage 2 sleep (β: 0.205; CI: 0.001-0.409; p=0.05) and REM 
latency (β: 0.234; CI: 0.001-0.468; p=0.05) after adjustment for potential confounders. 
Conclusion: Depressive symptoms among kTx recipients are associated with increased amount of stage 
2 sleep and prolonged REM latency. Further studies are needed to confirm our findings and understand 
potential clinical implications. 
 
BRIEF SUMMARY 
Current Knowledge/Study Rationale: Depression and sleep problems are very prevalent in kidney 
transplant recipients. However, the association between sleep structure and subjective depressive 
symptoms has not been investigated in this population. 
Study Impact: We demonstrate, for the first time, a connection between depressive symptoms and 
objectively assessed sleep macrostructure among kidney transplant recipients. These results represent 
an important step in the understanding of the underlying processes linking depression and sleep 
among these patients. 
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Depression is one of the most prevalent mental health conditions in patients with chronic 
kidney disease (CKD);1-4 furthermore it is an important determinant of impaired quality of life5,6. Among 
kidney transplant (kTx) recipients depression is associated with reduced adherence and also with 
increased morbidity, graft loss and mortality7-13. Poor sleep and various sleep problems are also 
frequent complaints among kTx recipients14,15. Earlier we reported that chronic insomnia was 
independently associated with the presence of depression in kTx recipients16. 
In the general population there is a strong and bidirectional relationship between depression 
and sleep17. This is also reflected in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) 
definition of major depression (MD),18 as sleep complaints are core symptoms of MD. Several objective 
sleep parameters are different in MD patiens than in healthy controls. Patients with MD have 
decreased amount of slow wave sleep (SWS) and shortened rapid eye movement (REM) latency with 
increased amount of REM sleep19-22. 
The exact mechanisms and factors that may link depression to poor clinical outcomes among 
kTx recipients are not well defined yet. In a recent review focusing on kTx and depression23 sleep is not 
at all mentioned. This may be due to the complete lack of polysomnography (PSG) studies that assess 
the association between sleep and depression in this population. The frequent co-occurance of 
subjective sleep complaints and depression among kTx recipients16 suggests that the relationship 
between the two conditions may be similar to the association described in the general population24-26. 
This highlights the clinical significance of sleep problems among kTx recipients, since they are 
potentially modifiable and interventions focusing on enhancing sleep may help to improve depressive 
symptoms27. 
Despite the significance of depression among kTx recipients and its well-known associations 
with sleep problems in the general population, there is a lack of information regarding the connection 
of depression and sleep parameters assessed by PSG among kTx recipients. Evaluating sleep structure 
with PSG and its associations with depressive symptoms is an important step in the understanding of 
the pathophysiology behind the subjective symptoms. Thus, in this study, we aimed to investigate the 
macrostructure parameters of sleep and we hypothesized that, similarly to patients with depression, 
less SWS, shortened REM sleep latency and higher proportion of REM sleep are associated with 




Materials and methods 
 
Sample of patients and data collection 
Data for this analysis were obtained from the ‘‘SLeep disorders Evaluation in Patients after kidney 
Transplantation (SLEPT) study’’28-34. Potentially eligible patients were selected from all prevalent adult 
kTx recipients (‘‘total clinic population’’; n = 1,214) who were regularly followed at a single outpatient 
academic transplant center, the kidney transplant clinic of the Department of Transplantation and 
Surgery at the Semmelweis University, Budapest, Hungary (Figure 1). All patients followed at the clinic 
on December 31, 2006 were considered for enrollment in the Malnutrition and inflammation in 
transplant (MINIT-HU) study. After applying exclusion criteria (transplant received within less than 3 
months, presence of active and acute respiratory disorder, acute infection, or hospitalization within 1 
month, surgery within 3 months), 1,198 patients remained (‘‘base population’’). From this ‘‘base 
population,’’ we randomly selected and approached 150 patients (‘‘kTx study sample’’) using the 
simple random sampling strategy offered by SPSS 15.0 (IBM Corporation, Armonk, New York, USA). 
The creation of cohort has been described previously28-34. From these 150 eligible patients 100 
individuals agreed to participate and they underwent one-night PSG (’’kTx participant sample”). From 
this sample of 100 patients, 3 were excluded of our analysis because of missing depression score and 
2 were excluded because of antidepressant pharmacotherapy. Thus, the final ’’kTx macrostructure 
sample’’ included 95 patients whose PSG recordings were analysed in this report. Demographic, 
anamnestic and questionnaire-based data were collected at enrollment, including age, sex, etiology of 
end-stage kidney disease (ESKD), transplantation-related data, medication use, and assessment of 
depression and insomnia symptoms. 
 
Assessment of depression 
The Hungarian version of the Center for Epidemiologic Studies - Depression (CES-D) scale35 was 
prepared according to the recommended procedure36 and was validated by our team in Hungarian kTx 
recipients37. The CES-D scale consists of 20 items, the score range is 0-60, with higher scores indicating 
lower mood. Subjects are asked to grade how frequently their complaints occured and how long lasted 
(rarely, 1-2 days, 3-4 days, 5-7 days) within the last week. In the present analysis the CES-D score was 
used to describe the severity of depressive symptoms in the sample. In addition, a cut-off score of 18 
was used to estimate the frequency of clinically significant depression in patients with CKD as 





Polysomnography (PSG) and sleep staging 
Standard, attended overnight PSG was performed in acoustically isolated and video-monitored sleep 
laboratory equipped with four individual suits (SOMNOscreenTM PSG Tele, SOMNOmedics GmBH, 
Germany, CE0494). The following data were recorded: 5 EEG channels (A1, A2, C3, C4, Cz), 
electrooculogram, chin electromyography, tibial electromyography, electrocardiography, airflow, 
thoracic–abdominal movements, pulse oximetry, tracheal sound (snoring), and body position. The 
ground and common reference electrodes were placed at Fpz and Cz, respectively. EEG signals were 
sampled and stored at 128 Hz, low- and high-pass filters were set at 35 Hz and 0.2 Hz, respectively. All 
recordings were performed on weekdays, the timing of “lights off” and “lights on” were uniformly set 
around 22:00 and 6:00, respectively. 
Recordings were manually scored by two somnologists (MZM, ASL). Sleep stages were determined in 
30 sec epochs according to Rechtschaffen and Kales39. Sleep macrostructure was characterized by the 
following variables: sleep onset latency (SOL: time elapsed from “lights off ” to the first occurrence of 
sleep stage 2); total sleep time (TST); wake after sleep onset (WASO: time spent awake from sleep 
onset to “lights on”), sleep efficiency (ratio of total sleep time over the time spent in bed); percentages 
of stages 1, 2, slow wave sleep (SWS: stages 3 and 4 combined) and percentage and latency of REM 
sleep. Respiratory events, periodic leg movements and microarousals were scored according to 
standard criteria40,41. Apnea was defined as the absence of airflow for more than 10 sec; hypopnea was 
defined as a clearly discernible reduction in airflow for more than 10 sec associated with an arousal 
and/or 3% reduction in oxygen saturation. The apnea-hypopnea index (AHI) was defined as the number 
of apneas and hypopneas per hour of sleep. Periodic limb movements were defined as limb 
movements with duration of 0.5–5 sec; inter-movement interval of 5–90 sec; and separation criteria 
for limb movements occurring in both legs: more than 5 sec between onsets. The periodic limb 
movement index (PLMI) was defined as the number of limb movements per hours during sleep. 
 
Assessment of insomnia, restless legs syndrome and comorbidities 
The Athens Insomnia Scale (AIS) was used to assess sleep complaints and identify possible cases of 
insomnia42,43. The AIS consists of eight items, score range 0–24, with higher scores indicating worse 
sleep. Subjects are asked to grade the severity of the sleep complaints (absent, mild, severe, very 
severe) only if the particular complaint occurred at least three times per week during the last month. 
A cut-off score of 10 has been suggested for epidemiological studies, providing acceptable sensitivity 
and specificity to detect clinically significant insomnia43. The English version of the AIS had been 
previously translated and validated by our group44. 
Symptoms of restless legs syndrome (RLS) were identified by using the RLS Questionnaire (RLSQ) 
completed by the patients. The original version of the RLSQ had been carefully developed to cover the 
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four diagnostic criteria of RLS and was shown to be a reliable screening instrument45. The original 
instrument was used in an epidemiologic survey46 and the Hungarian version was used in our earlier 
studies involving different populations with CKD47-49. 
Comorbidity was assessed by the modified Charlson Comorbidity Index50 completed by the main 
responsible transplant physician of the participant. Information about medication use was obtained 
from the questionnaires and the medical charts. 
 
Laboratory data 
Laboratory data were extracted from the medical charts, including blood hemoglobin, serum albumin 
and creatinine. Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI (Chronic 
Kidney Disease EPIdemiology collaboration) formula51. 
 
Transplantation and donor related data 
Transplantation-related information collected included current medications, transplant and dialysis 
‘‘vintage’’ (i.e., time elapsed since transplantation or time spent on dialysis prior to transplantation), 
history of acute rejection, age and sex of donor and history of delayed graft function. Time elapsed 
since the initiation of the first treatment for ESKD - cumulative ESKD time - was also calculated. 
Standard maintenance immunosuppressant (IS) therapy generally consisted of prednisolone, either 
cyclosporine A microemulsion formulation or tacrolimus, combined with mycophenolate mofetil or 
azathioprine, everolimus or sirolimus. 
 
Ethics approval 
The study was approved by the Ethics Board of the Semmelweis University (4/2007). Before 
enrollment, patients received detailed verbal and written information about the aims and protocol of 
the study and signed an informed consent. 
 
Statistical analysis 
Statistical analysis was carried out using STATA 13.0 software. Continuous variables were compared 
using Student’s t-test or the Mann-Whitney U test, as appropriate. Categorical variables were analyzed 
using the chi-square test or the Fisher's exact test if the observation numbers were low. Bivariate 
analysis was performed using Pearson and Spearman rank correlation analysis. 
We analyzed the association between the CES-D score and the selected sleep macrostructure 
parameters with multivariable linear regression analyses. The models were built with the sleep 
parameter as the dependent variable and the CES-D score as independent variable. In the models the 
potential confounders, which were selected based on theoretical considerations, were additionally 
7 
 
subject to backward stepwise selection using a removal condition (p>0.2): AIS score, graft function 
(eGFR), AHI, PLMI, presence or absence of RLS and hypnotic medication use. Age, sex and CES-D score 
were included in the models with forced selection. We used square root transformation to achieve 
normal distribution of the variable where it was necessary (REM latency). In all statistics, two-sided 
tests were used and p<0.05 was considered statistically significant. 
 
Results 
Demographic data and baseline characteristics of the sample 
Of the 150 eligible patients (‘‘kTx study sample,’’ see „Methods” above), 50 individuals (33%) refused 
to participate. Consequently, the ‘‘kTx participant sample’’’ who underwent PSG included 100 Tx 
patients (Figure 1). There were no significant differences regarding age and sex between participants 
and those who refused to participate (data not shown). The basic characteristics (age, sex, eGFR, serum 
albumin) of the ‘‘kTx participant sample’’ were similar to the characteristics of the ‘‘total clinic 
population’’ (data not shown). 
Of the 100 patients in the ’’kTx participant sample’’ we excluded 5 patients; 3 patients had missing 
CES-D score and 2 patients were excluded because of treatment with antidepressant medication. Thus, 
the final ’’kTx macrostructure sample’’ included 95 patients (Figure 1). The demographic and 
laboratory parameters, the comorbid conditions and transplantation related data of the ’’kTx 
macrostructure sample” are presented in Table 1. 
 
Prevalence and severity of depression and associations with demographics 
The median of the CES-D score was 10 (IQR: 11) in the sample. One fifth of the patients scored 18 or 
higher indicating high risk of depressive symptoms38 (Table 1). High depression risk was associated with 
high risk of insomnia and RLS, furthermore, these patients were taking significantly more hypnotic 
medication. Female gender and dialysis vintage were nearly significantly related to high depression 
risk. 
 
Association between depressive symptoms and sleep quality 
High risk for depression was significantly associated with less REM sleep and longer REM latency. 
Additionally, there was a tendency for more stage 2 sleep (Table 2). The proportion of SWS was not 
associated with high risk for depression (Table 2). CES-D score, a continuous measure of depression 
symptom severity, was significantly associated with subjective insomnia complaints as measured by 
the AIS score, with more stage 2 sleep, longer REM latency and less REM sleep, but not with the 




To assess the independent association between depressive symptoms and sleep macrostructure we 
utilized multivariable analysis (Table 4). The selected sleep macrostructure parameters (proportion of 
SWS and REM sleep, REM sleep latency) were included in the multivariable models as dependent 
variables. Additionally, we also included the proportion of stage 2 sleep as dependent variable based 
on the results of the univariable analyses. Higher proportion of stage 2 sleep and longer REM latency 
were significantly associated with depression severity independent of other covariables. However, the 
association of REM sleep percentage with the CES-D score diminished after controlling for covariables. 
Similarly, the proportion of SWS was not associated with the CES-D score in the multivariable analysis. 
 
Discussion 
As far as we know, this is the first study that assessed the association of depressive symptoms 
and sleep architecture of kTx recipients. Our main finding is that severity of depressive symptoms is 
associated with increased proportion of stage 2 sleep and longer REM latency, independently of 
important covariables. In our dataset depressive symptoms were not associated with decreased SWS 
among kTx recipients. 
There has been a growing interest in detailed assessment of sleep among patients with various 
stages of CKD52-54 and there is an increasing focus on patient reported outcomes55. However, these 
earlier studies were performed using in-home PSG and did not particularly focus on kTx recipients. 
Laboratory assessed PSG studies among the kTx recipient population included much fewer patients (n1 
= 18; n2 = 9; n3 = 34, respectively) and mainly focused on sleep apnea and the change of the sleep 
structure associated with apnea treatment or transplantation56-58. Although some sleep 
macrostructure parameters were reported in these studies, little attention was paid to stage 2 sleep 
or REM sleep. 
We found a significant association of stage 2 sleep with depressive symptoms among kTx 
recipients. Another study that assessed the sleep architecture of patients with CKD and ESKD reported 
significant association between increased stage 2 sleep and severe fatigue52, without the significant 
involvement of SWS. This association, however, was not analyzed in multivariable analysis. 
Interestingly, Smagula et al. also described increased stage 2 sleep (but not decreased SWS) 
associated with depressive symptoms among older men in a community-dwelling sample59. They 
interpreted their result as a sign of accelerated age-related change in the sleep structure among this 
population. They also highlighted that the severity of depressive symptoms and the lack of treatment-
seeking behaviour of these participants were different from depressed in-patients. According to their 
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opinion59, these differences might contribute to the sleep architecture variation60 they reported in this 
sample. 
In fact, increased stage 2 sleep is not a characteristic feature of the sleep architecture of 
patients diagnosed with MD19-21. However, in a randomized placebo controlled trial a significant 
improvement of low mood in olanzapine-treated participants was associated with changes mainly in 
sleep continuity measures and also the duration of stage 2 sleep, but not with the change of SWS61. 
Within this kTx population, we observed a surprisingly prolonged REM latency and decreased 
REM sleep compared to normal values widely-used in sleep medicine62. According to our current 
analysis, the prolongation of REM sleep latency and the consequent decrease of REM percentage may 
be both connected with depression. 
In earlier PSG studies among kTx recipients the proportion of REM sleep was variable, from 
normal (21.6±5.9 %; 18.9±8.3 %)56,58 to low (14±9.2 %)57. REM latency was only reported in one paper 
(133±76 min)57. Interestingly, the proportion of REM sleep was also associated with declining renal 
function in patients with CKD, however, this association diminished after controlling for covariables54. 
Depressive symptoms were not considered in any of the previously mentioned studies. 
In a recent population-based study longer REM latency was associated with depressive 
symptoms (also measured by the CES-D score) even after adjustment for age and sex63. In the work of 
Smagula et al. shorter REM sleep was associated with more depressive symptoms59. Although 
shortening of REM latency and more REM sleep are thought to be markers of depression, not every 
patient with depression is characterized by dysregulated REM sleep19,21. Similarly, population-based 
studies sometimes report no association of REM parameters with depressive symptoms64,65. 
Contrary to our expectation, we did not find a significant association between depressive 
symptoms and SWS among kTx recipients. Similarly, there was no association between SWS and 
depressive symptoms in a large community sample (n = 2,861)59. It is possible that the relationship 
between depressive symptoms and SWS is modified by unique characteristics of certain populations 
(such as age, comorbidities, medications, etc). The pathophysiology of the illness, metabolic changes 
or the impact of medications may all be causes of variations in sleep architecture60,63 that may alter 
the expected patterns described in patients with MD17,19,20. In this respect it is also interesting to note 
that SWS was higher in patients on dialysis compared to pre-dialysis or transplanted patients53,56. These 
results may indicate that the modality of the renal replacement therapy or the kidney disease itself 
may affect SWS and the regulation of NREM sleep in some yet undefined way. It is also possible, that 
the lack of significant association was due to the relatively small sample size and the consequently low 
statistical power. 
One explanation of the observed sleep architecture variations may be that a sleep-protecting 
mechanism is over activated during NREM sleep among kTx recipients. Such a mechanism would 
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preserve SWS, but also would lead to the prolonged REM latency. Altered homeostasis of SWS could 
be investigated with exploring sleep microstructure including analyses of spindles, K-complexes and 
cyclic alternating pattern66,67. 
Several limitations of our study should be considered when interpreting the results. First, this 
is a cross-sectional study and this prevents us to draw conclusions about causality or temporality. 
Second, we did not have a control group, therefore we could not compare the sleep architecture with 
healthy sleepers. Third, it is possible that the impaired kidney function of kTx recipients might have 
influenced our findings. In this regards it is important to note, that we adjusted our multivariable 
models for eGFR, a generally used parameter to characterize graft function. eGFR is reportedly 
associated with sleep structure in earlier stages of CKD54. Forth, we also considered sleep disorders as 
potential confounders while building our models. Importantly, these variables did not alter the 
associations we report. Additional limitations of our study design were described previously (first-night 
effect, the use of multiple medications)62. 
In summary, we found that increased depressive symptom severity was significantly associated 
with higher stage 2 sleep percentage and prolonged REM latency in kTx recipients. These results may 
be related to the unique characteristics of this population and may suggest that a sleep protecting 
mechanism is associated with depressive symptoms among kTx recipients. Additionally, the altered 
NREM sleep regulation could partly be connected to the loss of REM sleep. Further research is needed 
to better understand the complex relationship between depressive symptoms and sleep structure 
among kTx recipients. 
Based on our findings we propose that depression among this patient population should be 
treated as a different subtype, and in case of pharmacological treatment the prolonged REM latency 
and low amount of REM sleep should be taken into consideration. Future studies are also warranted 
to define the most effective treatment for depression in this patient population. Furthermore, future 
research should also focus on whether psychotherapy targeting sleep problems would change these 
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